Standard Chemical & Pharmaceutical Co. Ltd.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. carries a market capitalization of 11.31B, placing it among publicly traded companies globally. Its enterprise value stands at 13.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. has 196.57M shares outstanding.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. trades at a trailing price-to-earnings ratio of 11.28. The price-to-sales ratio is 1.64, and the price-to-book ratio stands at 1.83.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 6.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.06 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Standard Chemical & Pharmaceutical Co. Ltd. trades at an EV/FCF ratio of 11.01, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 13.16B versus a market cap of 11.31B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.12, indicating elevated leverage, while an interest coverage ratio of 196.81 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. posted a return on equity (ROE) of 17.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.76 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.59, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.86, useful for judging operating efficiency across full business cycles. The company generates approximately 3.94M in revenue per employee across its workforce of 1,795.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.47 indicates how many times Standard Chemical & Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. recorded 306.45M in income tax expense. That works out to an effective tax rate of 18.13, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.69B, leaving 1.03B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Standard Chemical & Pharmaceutical Co. Ltd.'s stock has gained approximately 11.96% over the past 52 weeks. The 50-day moving average sits at 56.47, while the 200-day moving average is 56.53.

Over the twelve months ended June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. generated 7.08B in revenue and converted that into 1.03B in net income, yielding earnings per share of 6.85. EBITDA reached 1.89B, while operating income came in at 1.45B.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. holds 2.32B in cash and equivalents against 1.04B in total debt, resulting in a net debt position of -1.20B. Total book value stands at 6.19B, with working capital of 3.13B providing operational flexibility.

Standard Chemical & Pharmaceutical Co. Ltd. produced 1.65B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -459.64M in capital expenditures, free cash flow totaled 1.19B - equivalent to 5.90 per share.

Over the twelve months ended June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. posted a gross margin of 42.60, reflecting its pricing power and cost economics. The operating margin of 20.51 and net profit margin of 14.51 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.22, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Standard Chemical & Pharmaceutical Co. Ltd. shareholders.

Standard Chemical & Pharmaceutical Co. Ltd.'s most recent stock split took place on July 23, 2026 with a 10:11 split ratio.

As of June 30, 2026, Standard Chemical & Pharmaceutical Co. Ltd. has an Altman Z-Score of 3.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.